Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy.

MLA

Ortiz-Maldonado, Valentín, et al. “Factors Associated with the Clinical Outcome of Patients with Relapsed/Refractory CD19 + Acute Lymphoblastic Leukemia Treated with ARI-0001 CART19-Cell Therapy.” Journal for Immunotherapy of Cancer, vol. 9, no. 12, Dec. 2021. EBSCOhost, https://doi.org/10.1136/jitc-2021-003644.

APA

Ortiz-Maldonado, V., Rives, S., Español-Rego, M., Alonso-Saladrigues, A., Montoro, M., Magnano, L., Giné, E., Pascal, M., Díaz-Beyá, M., Castella, M., Català, A., Faura, A., Rodríguez-Lobato, L. G., Oliver-Caldes, A., Martínez-Roca, A., Rovira, M., González-Navarro, E. A., Ortega, J. R., Cid, J., … Delgado, J. (2021). Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. Journal for Immunotherapy of Cancer, 9(12). https://doi.org/10.1136/jitc-2021-003644

Chicago

Ortiz-Maldonado, Valentín, Susana Rives, Marta Español-Rego, Anna Alonso-Saladrigues, Mercedes Montoro, Laura Magnano, Eva Giné, et al. 2021. “Factors Associated with the Clinical Outcome of Patients with Relapsed/Refractory CD19 + Acute Lymphoblastic Leukemia Treated with ARI-0001 CART19-Cell Therapy.” Journal for Immunotherapy of Cancer 9 (12). doi:10.1136/jitc-2021-003644.